DANIEL K SPIEGELMAN Insider Trading Transactions

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for DANIEL K SPIEGELMAN.

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of DANIEL K SPIEGELMAN. DANIEL K SPIEGELMAN is Senior Vice President and CFO in CV THERAPEUTICS INC ($CVTX) and Director in MYRIAD GENETICS INC ($MYGN) and EVP, Chief Financial Officer in BIOMARIN PHARMACEUTICAL INC ($BMRN) and Director in Oncothyreon Inc. ($ONTY) and Director in Relypsa Inc ($RLYP).

Latest Insider Trading Transactions of DANIEL K SPIEGELMAN

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, BMRN, CASC, CVTX, MYGN, RLYP

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
May 28 2021	MYGN	MYRIAD GENETICS IN ...	SPIEGELMAN DANIEL K	Director	Sell	D	0.00	15,889	0	20,562	36.5 K to 20.6 K (-43.59 %)
Dec 07 2020	MYGN	MYRIAD GENETICS IN ...	SPIEGELMAN DANIEL K	Director	Grant	A	0.00	15,889	0	36,451	20.6 K to 36.5 K (+77.27 %)
May 28 2020	MYGN	MYRIAD GENETICS IN ...	SPIEGELMAN DANIEL K	Director	Grant	A	0.00	20,562	0	20,562	0 to 20.6 K
Jun 07 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	68.78	176	12,106	47,686	47.5 K to 47.7 K (+0.37 %)
Apr 03 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	89.00	13,473	1,199,097	47,510	61 K to 47.5 K (-22.09 %)
Mar 29 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	90.00	100	9,000	60,983	61.1 K to 61 K (-0.16 %)
Mar 26 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	88.05	3,598	316,804	61,083	64.7 K to 61.1 K (-5.56 %)
Mar 19 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	A	94.53	23,450	2,216,729	23,450
Mar 19 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	9,370	0	64,681	55.3 K to 64.7 K (+16.94 %)
Mar 19 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	94.53	7,227	683,168	55,311	62.5 K to 55.3 K (-11.56 %)
Mar 05 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	94.76	912	86,421	62,538	63.5 K to 62.5 K (-1.44 %)
Mar 05 2019	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	12,205	0	63,450	51.2 K to 63.5 K (+23.82 %)
Dec 20 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	68.78	175	12,037	51,245	51.1 K to 51.2 K (+0.34 %)
Jun 26 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	99.01	472	46,733	51,070	51.5 K to 51.1 K (-0.92 %)
Jun 26 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	99.00	9,528	943,272	51,542	61.1 K to 51.5 K (-15.60 %)
Jun 26 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	99.01	472	46,733	51,070	51.5 K to 51.1 K (-0.92 %)
Jun 26 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	99.00	9,528	943,272	51,542	61.1 K to 51.5 K (-15.60 %)
Jun 06 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	92.07	1,711	157,532	61,070	62.8 K to 61.1 K (-2.73 %)
Jun 06 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	68.78	167	11,487	62,781	62.6 K to 62.8 K (+0.27 %)
Apr 25 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	82.15	11,059	908,497	62,543	73.6 K to 62.5 K (-15.03 %)
Apr 25 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	82.15	11,059	908,497	62,543	73.6 K to 62.5 K (-15.03 %)
Mar 26 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	81.36	3,583	291,513	73,602	77.2 K to 73.6 K (-4.64 %)
Mar 19 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	A	83.57	39,900	3,334,443	39,900
Mar 19 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	12,480	0	77,185	64.7 K to 77.2 K (+19.29 %)
Mar 19 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	83.57	3,815	318,820	64,705	68.5 K to 64.7 K (-5.57 %)
Mar 13 2018	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Option Exercise	D	0.00	13,927	0	0
Mar 13 2018	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Sell	U	0.00	21,006	0	0	21 K to 0 (-100.00 %)
Mar 06 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	79.86	1,609	128,495	68,520	70.1 K to 68.5 K (-2.29 %)
Feb 28 2018	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	12,529	0	70,129	57.6 K to 70.1 K (+21.75 %)
Sep 26 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Option Exercise	M	0.00	2,375	0	0
Sep 26 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Payment of Exercise	F	3.94	594	2,340	21,006	21.6 K to 21 K (-2.75 %)
Sep 26 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Buy	M	0.00	2,375	0	21,600	19.2 K to 21.6 K (+12.35 %)
Jun 27 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Option Exercise	M	0.00	9,058	0	0
Jun 27 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Payment of Exercise	F	3.78	2,265	8,562	19,225	21.5 K to 19.2 K (-10.54 %)
Jun 27 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Buy	M	0.00	9,058	0	21,490	12.4 K to 21.5 K (+72.86 %)
Jun 13 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Option Exercise	M	0.00	2,148	0	0
Jun 13 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Option Exercise	A	0.00	13,927	0	13,927
Jun 13 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Payment of Exercise	F	3.34	537	1,794	12,432	13 K to 12.4 K (-4.14 %)
Jun 13 2017	CASC	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Buy	M	0.00	2,148	0	12,969	10.8 K to 13 K (+19.85 %)
Jun 06 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	90.72	1,801	163,387	23,303	25.1 K to 23.3 K (-7.17 %)
May 17 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	91.50	1,722	157,563	25,104	26.8 K to 25.1 K (-6.42 %)
May 17 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	70.30	155	10,897	26,826	26.7 K to 26.8 K (+0.58 %)
Mar 24 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	A	87.42	39,480	3,451,342	39,480
Mar 24 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	12,200	0	26,671	14.5 K to 26.7 K (+84.31 %)
Mar 17 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	91.96	1,989	182,908	14,471	16.5 K to 14.5 K (-12.08 %)
Mar 17 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	92.50	4,301	397,843	16,460	20.8 K to 16.5 K (-20.72 %)
Mar 08 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	93.32	2,303	214,916	20,761	23.1 K to 20.8 K (-9.99 %)
Mar 07 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	93.95	2,283	214,488	23,064	25.3 K to 23.1 K (-9.01 %)
Jan 10 2017	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	90.00	5,000	450,000	18,100	23.1 K to 18.1 K (-21.65 %)
Nov 14 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	90.61	20,000	1,812,206	23,100	43.1 K to 23.1 K (-46.40 %)
Nov 14 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	68.44	156	10,677	43,100	42.9 K to 43.1 K (+0.36 %)
Sep 02 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Option Exercise	D	17.00	4,500	76,500	0
Sep 02 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Option Exercise	D	35.79	4,500	161,055	0
Sep 02 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Option Exercise	D	23.96	12,000	287,520	0
Sep 02 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Sell	D	32.00	2,250	72,000	0	2.3 K to 0 (-100.00 %)
Sep 02 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Sell	U	32.00	1,237	39,584	2,250	3.5 K to 2.3 K (-35.47 %)
Aug 03 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	99.33	4,000	397,320	42,944	46.9 K to 42.9 K (-8.52 %)
Jun 28 2016	ONTY	Cascadian Therapeu ...	SPIEGELMAN DANIEL K	Director	Option Exercise	A	0.00	54,347	0	54,347
Jun 23 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Option Exercise	A	17.00	4,500	76,500	4,500
Jun 23 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Grant	A	0.00	2,250	0	3,487	1.2 K to 3.5 K (+181.89 %)
Jun 08 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	89.14	1,649	146,992	46,944	48.6 K to 46.9 K (-3.39 %)
Jun 08 2016	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Sell	S	19.31	1,013	19,562	1,237	2.3 K to 1.2 K (-45.02 %)
Jun 07 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	90.00	1,801	162,090	48,593	50.4 K to 48.6 K (-3.57 %)
Jun 02 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	M	39.06	16,896	659,958	2,604
Jun 02 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	89.35	3,945	352,486	50,394	54.3 K to 50.4 K (-7.26 %)
Jun 02 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	90.00	16,896	1,520,640	54,339	71.2 K to 54.3 K (-23.72 %)
Jun 02 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Buy	M	39.06	16,896	659,958	71,235	54.3 K to 71.2 K (+31.09 %)
May 31 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	89.09	4,305	383,532	54,339	58.6 K to 54.3 K (-7.34 %)
May 25 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	87.07	3,769	328,184	58,644	62.4 K to 58.6 K (-6.04 %)
May 17 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	82.71	1,722	142,427	62,413	64.1 K to 62.4 K (-2.68 %)
May 17 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	51.26	202	10,355	64,135	63.9 K to 64.1 K (+0.32 %)
Mar 17 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	A	83.43	37,290	3,111,105	37,290
Mar 17 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	16,640	0	63,933	47.3 K to 63.9 K (+35.18 %)
Mar 07 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	89.57	2,395	214,520	47,293	49.7 K to 47.3 K (-4.82 %)
Mar 02 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	86.12	4,623	398,120	49,688	54.3 K to 49.7 K (-8.51 %)
Mar 02 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	81.87	46,766	3,828,732	54,311	101.1 K to 54.3 K (-46.27 %)
Feb 26 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	5,883	0	101,077	95.2 K to 101.1 K (+6.18 %)
Feb 26 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	49,600	0	95,194	45.6 K to 95.2 K (+108.79 %)
Feb 26 2016	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	17,150	0	45,594	28.4 K to 45.6 K (+60.29 %)
Nov 18 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	M	39.06	20,000	781,200	19,500
Nov 18 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	104.30	20,000	2,085,918	28,229	48.2 K to 28.2 K (-41.47 %)
Nov 18 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Buy	M	39.06	20,000	781,200	48,229	28.2 K to 48.2 K (+70.85 %)
Sep 28 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Option Exercise	A	0.00	14,245	0	14,245
Jun 16 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Option Exercise	M	0.00	16,042	0	0
Jun 16 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Option Exercise	A	0.00	12,886	0	12,886
Jun 16 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Payment of Exercise	F	3.88	4,011	15,563	52,675	56.7 K to 52.7 K (-7.08 %)
Jun 16 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Buy	M	0.00	16,042	0	56,686	40.6 K to 56.7 K (+39.47 %)
Jun 08 2015	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Option Exercise	A	35.79	4,500	161,055	4,500
Jun 08 2015	RLYP	Relypsa Inc	SPIEGELMAN DANIEL K	Director	Grant	A	0.00	2,250	0	2,250	0 to 2.3 K
Jun 08 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	122.30	1,649	201,669	28,229	29.9 K to 28.2 K (-5.52 %)
Jun 08 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	120.46	1,801	216,948	29,878	31.7 K to 29.9 K (-5.69 %)
Jun 03 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	124.16	3,945	489,811	31,679	35.6 K to 31.7 K (-11.07 %)
Jun 03 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	126.15	1,578	199,065	35,624	37.2 K to 35.6 K (-4.24 %)
Jun 03 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	125.57	4,305	540,579	37,202	41.5 K to 37.2 K (-10.37 %)
May 28 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	130.00	34,078	4,430,140	41,507	75.6 K to 41.5 K (-45.09 %)
May 19 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Buy	S	124.77	2,059	256,905	75,585	73.5 K to 75.6 K (+2.80 %)
May 19 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Payment of Exercise	F	122.78	1,722	211,427	77,644	79.4 K to 77.6 K (-2.17 %)
May 19 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	51.26	88	4,511	79,366	79.3 K to 79.4 K (+0.11 %)
Apr 01 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Buy	P	1.59	10,000	15,856	40,644	30.6 K to 40.6 K (+32.63 %)
Apr 01 2015	ONTY	Oncothyreon Inc.	SPIEGELMAN DANIEL K	Director	Buy	P	1.63	10,000	16,271	30,644	20.6 K to 30.6 K (+48.44 %)
Mar 05 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	A	108.36	23,900	2,589,804	23,900
Mar 05 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Grant	A	0.00	10,500	0	79,278	68.8 K to 79.3 K (+15.27 %)
Mar 04 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Option Exercise	M	39.06	15,500	605,430	39,500
Mar 04 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Sell	S	107.00	15,500	1,658,500	68,676	84.2 K to 68.7 K (-18.41 %)
Mar 04 2015	BMRN	BIOMARIN PHARMACEU ...	SPIEGELMAN DANIEL K	EVP, Chief Financia ...	Buy	M	39.06	15,500	605,430	84,176	68.7 K to 84.2 K (+22.57 %)
Apr 08 2004	CVTX	CV THERAPEUTICS IN ...	SPIEGELMAN DANIEL K	Senior Vice Preside ...	Grant	A	14.67	682	10,005	1,524	842 to 1.5 K (+81.00 %)

Page: 1